An add-on Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-epileptic Drugs (AEDs)
The purpose of this study is to explore the maximum tolerated dose of E2007 in Japanese patients with refractory partial seizures which are uncontrolled with other anti-epileptic drugs (AEDs). Thirty patients will receive E2007 (dose escalating to the maximum of 12 mg per day). The dose of E2007 will be adjusted during 6 weeks. Subsequently, the dose will be fixed and maintained during 4 weeks.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Phase II, Open-label, Ascending High-dose, add-on Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-epileptic Drugs (AEDs)|
- Maximum Tolerated Dose (MTD) [ Time Frame: 10 weeks (Titration and Maintenance Periods) ] [ Designated as safety issue: No ]MTD was defined by participants. For participants who completed treatment, MTD was dose at last administration. For subjects who discontinued due to adverse event (AE), the MTD depended on the number of days within down-titration. If these criteria were not applied, the MTD was determined based on suggestions from the Tolerability and Safety Evaluation Committee.
- Percent Change in Total Seizure Frequency Per 28 Days From Baseline (Maintenance Period) ; LOCF [ Time Frame: Baseline (Day -28 to Day 0), Week 1 to Week 10 ] [ Designated as safety issue: No ]The percent change in seizure frequency per 28 days during the maintenance period was collected via patient diary cards. This was calculated using the last observation carried forward (LOCF) method.
|Study Start Date:||April 2009|
|Study Completion Date:||November 2009|
|Primary Completion Date:||November 2009 (Final data collection date for primary outcome measure)|
The dose of E2007 will start from 2 mg and will be increased by 2 mg every week up to 12 mg (the maximum dose). The dose will be adjusted during 6 weeks (i.e., titration period). Subsequently, the dose will be fixed and maintained during 4 weeks (Maintenance period). Patients must visit study site at Weeks -4, 1, 2, 3, 4, 5, 6, 8, 10 and 14 to confirm.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00849212
|Kitakyushu, Fukuoka, Japan|
|Kobe, Hyogo, Japan|
|Sendai, Miyagi, Japan|
|Komatsushima, Tokushima, Japan|
|Kodaira, Tokyo, Japan|
|Study Director:||Hidetaka Hiramatsu||New Drug Development Department, Eisai Company Limited|